Holen Sie sich die Stockscreener-App
26.82
0.09%
-0.045
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.86
Offen:
$27.02
24-Stunden-Volumen:
6.12M
Relative Volume:
0.13
Marktkapitalisierung:
$152.56B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
19.79
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
-0.79%
1M Leistung:
-2.70%
6M Leistung:
+12.42%
1J Leistung:
+4.82%
1-Tages-Spanne:
$26.79
$27.28
1-Wochen-Bereich:
$26.36
$27.41
52-Wochen-Spanne:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.83 | 152.73B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
991.24 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.52 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
222.28 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
190.57 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.31 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance Singapore
Pfizer's Top Legal Officer Nets Almost $2.3M More In 2025 - Law360
Lobbying Update: $2,870,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Self-represented worker’s 64-page Pfizer claim struck for violating pleading rules - HR Law Canada
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline - TipRanks
How Investors Are Reacting To Pfizer (PFE) Phase 2 Win For Tilrekimig In Atopic Dermatitis - simplywall.st
Form DEF 14A PFIZER INC For: Apr 23 - StreetInsider
The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income - Barchart.com
Franklin Resources Inc. Raises Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Mackenzie Financial Corp Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer’s Weight Management Drug Wins China Approval - Insider Monkey
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case - Reuters
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Pfizer streamlines LC/UV/MS data processing, analysis and reporting - Chromatography Today
Improving method transfer: How Pfizer uses method development software - Chromatography Today
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study - TipRanks
Dilated Cardiomyopathy Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Bristol Myers Squibb, Berlin Cures, Cumberland Pharma, Vericel Corp, Corimmun GmbH, Pfizer, Constant Therapeut - Barchart.com
One Pediatric Gastroenterologist’s Mission to Expand Pediatric Treatment Options - Pfizer
651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA - MarketBeat
Nasal Vaccines Market Is Going to Boom Rapidly | Pfizer • Moderna • GlaxoSmithKline - openPR.com
Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc.: No turn-around in sight - marketscreener.com
Pfizer Stock: Cheap For A Reason (NYSE:PFE) - Seeking Alpha
Pfizer’s Comirnaty update: what the new COVID shot really means for you - AD HOC NEWS
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Self -Care for Caregivers - Pfizer
PFIZER INC : UBS is Neutral - marketscreener.com
GIPR antagonists reported in Pfizer patent - bioworld.com
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity - FinancialContent
Van ECK Associates Corp Sells 4,744,499 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE): Impact from BioNTech Partnership in 2026 - GuruFocus
Legal & General Group Plc Purchases 3,296,415 Shares of Pfizer Inc. $PFE - MarketBeat
Banque Cantonale Vaudoise Sells 92,252 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Swiss National Bank Trims Stake in Pfizer Inc. $PFE - MarketBeat
562,908 Shares in Pfizer Inc. $PFE Bought by WINTON GROUP Ltd - MarketBeat
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Reuters
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):